Differences in coronary blood flow in aortic regurgitation and systemic arterial hypertension have implications for diastolic blood pressure targets: A systematic review and meta-analysis

Clinical Cardiology

Volumn 36, Issue 12, 2013, Pages 728-736

  Rabkin, Simon W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; BLOOD FLOW VELOCITY; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DIASTOLE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; HEART CYCLE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW; SYSTOLE;

ANTIHYPERTENSIVE AGENTS; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; ARTERIAL PRESSURE; CORONARY CIRCULATION; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 84890127991     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22194     Document Type: Review

References (44)

1. Feigl EO, Neat GW, Huang AH,. Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow. J Mol Cell Cardiol. 1990; 22: 375-390.
2. Duncker DJ, Bache RJ,. Regulation of coronary blood flow during exercise. Physiol Rev. 2008; 88: 1009-1086.
3. Rabkin SW, Waheed A, Poulter R, et al. Myocardial perfusion pressure in patients with hypertension and coronary artery disease: implications for diastolic blood pressure targets in hypertension management. J Hypertens. 2013; 31: 975-982.
4. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006; 144: 884-893.
5. Bangalore S, Messerli FH, Wun CC, et al; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010; 31: 2897-2908.
6. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765-774.
7. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 1755-1762.
8. Cruickshank JM,. Clinical importance of coronary perfusion pressure in the hypertensive patient with left ventricular hypertrophy. Cardiology. 1992; 81: 283-290.
9. Panjrath GS, Chaudhari S, Messerli FH,. The J-point phenomenon in aggressive therapy of hypertension: new insights. Curr Atheroscler Rep. 2012; 14: 124-129.
10. Rabkin SW, Mathewson AL, Tate RB,. Predicting risk of ischemic heart disease and cerebrovascular disease from systolic and diastolic blood pressures. Ann Intern Med. 1978; 88: 342-345.
11. Bekeredjian R, Grayburn PA,. Valvular heart disease: aortic regurgitation. Circulation. 2005; 112: 125-134.
12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-2012.
13. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62: 1006-1012.
14. Ishibashi Y, Shimada T, Nosaka S, et al. Effects of heart rate on coronary circulation and external mechanical efficiency in elderly hypertensive patients with left ventricular hypertrophy. Clin Cardiol. 1996; 19: 620-630.
15. Hamada M, Kuwahara T, Shigematsu Y, et al. Relation between coronary blood flow and left ventricular mass in hypertension: noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. Hypertens Res. 1998; 21: 227-234.
16. Trimarco B, Vigorito C, Cuocolo A, et al. Reflex control of coronary vascular tone by cardiopulmonary receptors in humans. J Am Coll Cardiol. 1988; 11: 944-952.
17. Sasaki O, Hamada M, Hiwada K,. Effects of coronary blood flow on left ventricular function in essential hypertensive patients. Hypertens Res. 2000; 23: 239-245.
18. Nitenberg A, Antony I,. Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol. 1996; 27: 115-123.
19. Opherk D, Mall G, Zebe H, et al. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 1984; 69: 1-7.
20. Leschke M, Schoebel FC, Vogt M, et al. Reduced peripheral and coronary vasomotion in systemic hypertension. Eur Heart J. 1992; 13: 96-99.
21. Hamasaki S, Al Suwaidi J, Higano ST, et al. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol. 2000; 35: 1654-1660.
22. Misawa K, Nitta Y, Matsubara T, et al. Difference in coronary blood flow dynamics between patients with hypertension and those with hypertrophic cardiomyopathy. Hypertens Res. 2002; 25: 711-716.
23. Takechi S, Nomura A, Machida M, et al. Different coronary blood flow increase in left ventricular hypertrophy due to hypertension compared to hypertrophic cardiomyopathy at elevated heart rate. Hypertens Res. 2003; 26: 789-793.
24. Schwartzkopff B, Motz W, Frenzel H, et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993; 88: 993-1003.
25. Bertrand ME, LaBlanche JM, Tilmant PY, et al. Coronary sinus blood flow at rest and during isometric exercise in patients with aortic valve disease: mechanism of angina pectoris in presence of normal coronary arteries. Am J Cardiol. 1981; 47: 199-205.
26. Pichard AD, Smith H, Holt J, et al. Coronary vascular reserve in left ventricular hypertrophy secondary to chronic aortic regurgitation. Am J Cardiol. 1983; 51: 315-320.
27. Nitenberg A, Foult JM, Antony I, et al. Coronary flow and resistance reserve in patients with chronic aortic regurgitation, angina pectoris and normal coronary arteries. J Am Coll Cardiol. 1988; 11: 478-486.
28. Matsuo S, Tsuruta M, Hayano M, et al. Phasic coronary artery flow velocity determined by Doppler flowmeter catheter in aortic stenosis and aortic regurgitation. Am J Cardiol. 1988; 62: 917-922.
29. Hongo M, Goto T, Watanabe N, et al. Relation of phasic coronary flow velocity profile to clinical and hemodynamic characteristics of patients with aortic valve disease. Circulation. 1993; 88: 953-960.
30. Kisanuki A, Murayama T, Matsushita R, et al. Transesophageal Doppler echocardiographic assessment of left coronary blood flow velocity in chronic aortic regurgitation. Am Heart J. 1996; 131: 101-106.
31. Kume T, Kawamoto T, Okura H, et al. Mechanism of increasing systolic coronary flow velocity in patients with aortic regurgitation. J Heart Valve Dis. 2008; 17: 89-93.
32. Fujiwara T, Nogami A, Masaki H, et al. Coronary flow characteristics of left coronary artery in aortic regurgitation before and after aortic valve replacement. Ann Thorac Surg. 1988; 46: 79-84.
33. Folts JD, Rowe GG, Kahn DR, et al. Phasic changes in human right coronary blood flow before and after repair of aortic insufficiency. Am Heart J. 1979; 97: 211-215.
34. Tamborini G, Barbier P, Doria E, et al. Coronary flow and left ventricular diastolic function in aortic regurgitation. Coron Artery Dis. 1995; 6: 635-643.
35. Feldman RL, Nichols WW, Pepine CJ, et al. Influence of aortic insufficiency on the hemodynamic significance of a coronary artery narrowing. Circulation. 1979; 60: 259-268.
36. Brawley RK, Morrow AG,. Direct determinations of aortic blood flow in patients with aortic regurgitation: effects of alterations in heart rate, increased ventricular preload or afterload, and isoproterenol. Circulation. 1967; 35: 32-45.
37. Marcus ML, Mueller TM, Gascho JA, et al. Effects of cardiac hypertrophy secondary to hypertension on the coronary circulation. Am J Cardiol. 1979; 44: 1023-1028.
38. Kisanuki A, Matsushita R, Murayama T, et al. Transesophageal Doppler echocardiographic assessment of systolic and diastolic coronary blood flow velocities at baseline and during adenosine triphosphate-induced coronary vasodilation in chronic aortic regurgitation. Am Heart J. 1997; 133: 71-77.
39. Frohlich ED, González A, Díez J,. Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. J Hypertens. 2011; 29: 17-26.
40. Jüni P, Holenstein F, Sterne J, et al. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol. 2002; 31: 115-123.
41. Rosendorff C, Black HR, Cannon CP, et al. American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007; 115: 2761-2788.
42. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012; 60: e44-e164.
43. Daskalopoulou SS, Khan NA, Quinn RR, et al; Canadian Hypertension Education Program. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012; 28: 270-287.
44. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012; 33: 1635-1701.